How much does Cejemly (Sugemalimab Injection) Cost& price without insurance in China?
Cejemly® is the commercial brand name of Sugemalimab Injection, a fully human anti-programmed death ligand 1 (anti-PD-L1) monoclonal antibody developed by CStone Pharmaceuticals and Pfizer. It binds to PD-L1 expressed on tumor cells and immune cells, blocking its interaction with PD-1 and B7.1 receptors to restore the anti-tumor immune function of T cells.
Main Indications
First-line treatment of metastatic non-small cell lung cancer (NSCLC) in combination with platinum-based chemotherapy.
Treatment of unresectable stage III NSCLC with concurrent chemoradiotherapy.
Common Side Effects
Common mild adverse reactions: Fatigue, fever, rash, pruritus, diarrhea, and nausea.
Laboratory abnormalities: Decreased lymphocyte count, decreased neutrophil count, and elevated liver enzymes.
Severe but uncommon risks: Immune-related adverse events (including pneumonitis, colitis, hepatitis, endocrinopathies), severe infections, and infusion reactions.
Approval Status in China
Cejemly® (Sugemalimab Injection, 600mg/20.0mL) was officially approved for marketing in China in 2021. It is currently a prescription anti-tumor drug included in China’s National Medical Insurance List.
Buy Cejemly (Sugemalimab Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
